Literature DB >> 7614994

Mapping T cell recognition: the identification of a T cell receptor residue critical to the specific interaction with an influenza hemagglutinin peptide.

L R Wedderburn1, S J Searle, A R Rees, J R Lamb, M J Owen.   

Abstract

The fine specificity of T cell receptor (TCR) interaction with the influenza hemagglutinin peptide HA 307-319 in the context of the DR1 (DRA, DRB1 0101) and DR4 (DRA, DRB1 0404) was studied in two human T cell clones (HA1.7 and Cl-1) derived from different individuals. Sequencing of amplified TCR transcripts revealed that these two clones express highly related TCR alpha chains, with a conserved junctional motif, but very different TCR beta chains. Modeling studies led to the prediction that the conserved glutamic acid residue in the TCR alpha chain could interact with the lysine at position 316 in the peptide, a known TCR contact residue. HA1.7 TCR-CD3 zeta chimeric constructs were expressed in the rat basophil line (RBL) and shown to confer specific antigen recognition. In two TCR alpha chain mutants, with the conserved glutamic acid residue altered to alanine and lysine, respectively, peptide recognition was lost. Specific recognition was not rescued by altered peptide ligands. Furthermore, Jurkat derivatives expressing the related Jurkat TCR alpha chain paired with the HA 1.7 TCR beta chain did not recognize the HA 307-319/DR1 complex. These data provide evidence for the critical interaction of a TCR residue with antigenic peptide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614994     DOI: 10.1002/eji.1830250627

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.

Authors:  J Hennecke; A Carfi; D C Wiley
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 2.  Unusual features of self-peptide/MHC binding by autoimmune T cell receptors.

Authors:  Melissa J Nicholson; Michael Hahn; Kai W Wucherpfennig
Journal:  Immunity       Date:  2005-10       Impact factor: 31.745

3.  Antigen-specific T cell phenotyping microarrays using grating coupled surface plasmon resonance imaging and surface plasmon coupled emission.

Authors:  James M Rice; Lawrence J Stern; Ernest F Guignon; David A Lawrence; Michael A Lynes
Journal:  Biosens Bioelectron       Date:  2011-10-29       Impact factor: 10.618

4.  Flexibility in T-cell receptor ligand repertoires depends on MHC and T-cell receptor clonotype.

Authors:  A Geluk; K E van Meijgaarden; T H Ottenhoff
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

5.  Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire.

Authors:  H Hamlet Chu; James J Moon; Kensuke Takada; Marion Pepper; Jerry A Molitor; Timothy W Schacker; Kristin A Hogquist; Stephen C Jameson; Marc K Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-18       Impact factor: 11.205

6.  Preferential usage of the T-cell receptor by influenza virus hemagglutinin-specific human CD4+ T lymphocytes: in vitro life span of clonotypic T cells.

Authors:  A Prévost-Blondel; D Chassin; D Zeliszewski; I Dorval; G Sterkers; C Pannetier; J G Guillet
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity.

Authors:  Jens Hennecke; Don C Wiley
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

8.  Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers.

Authors:  Christopher J Holland; Pierre J Rizkallah; Sabrina Vollers; J Mauricio Calvo-Calle; Florian Madura; Anna Fuller; Andrew K Sewell; Lawrence J Stern; Andrew Godkin; David K Cole
Journal:  Sci Rep       Date:  2012-09-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.